Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment

Price, Vera H.; Menefee, Emory; Strauss, Paul

doi:10.1016/s0190-9622(99)70006-x

Cited by 136 publications

(77 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, none of these evaluated non-vellus hair growth nor was there a clear identification of the investigated frontotemporal area [7,13,14]. …”

Section: Discussionmentioning

confidence: 99%

“…In order to better understand the perception of clinical experts that minoxidil is also effective in stimulating hair growth in the frontotemporal area in AGA [7], we conducted a randomized placebo-controlled, double-blind, clinical study investigating the effect of twice daily 5% MTF on hair growth in both the frontotemporal and vertex regions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men

Hillmann

Bartels

Kottner

et al. 2015

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Background: 5% minoxidil formulations twice daily are effective in treating vertex male androgenetic alopecia (AGA); however, efficacy and safety data in frontotemporal regions are lacking. Objectives: To assess the efficacy of 5% minoxidil topical foam (5% MTF) in the frontotemporal region of male AGA patients after 24 weeks of treatment compared to placebo treatment and to the vertex region. Methods: Seventy males with moderate AGA applied 5% MTF or placebo foam (plaTF) twice daily for 24 weeks in frontotemporal and vertex regions. Target area non-vellus hair count (TAHC) was the primary end point. Results: Frontotemporal and vertex TAHC and target area cumulative non-vellus hair width (TAHW) showed similar responses to 5% MTF with significant increases up to week 16 compared to baseline (p < 0.001). After 24 weeks of treatment, frontotemporal TAHW increased significantly in the 5% MTF group compared to the plaTF group (p = 0.017), while TAHC showed a similar non-significant increase from baseline in both regions. At 24 weeks, 5% MTF users rated a significant improvement in scalp coverage for the frontotemporal (p = 0.016) and vertex areas (p = 0.027). Conclusions: 5% MTF twice a day promotes hair density and width in both frontotemporal and vertex regions in men with moderate stages of AGA.

show abstract

“…However, none of these evaluated non-vellus hair growth nor was there a clear identification of the investigated frontotemporal area [7,13,14]. …”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men

Hillmann

Bartels

Kottner

et al. 2015

Skin Pharmacol Physiol

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated that minoxidil applied twice a day is an effective treatment for AGA, in both men and women [5,49,[77][78][79][80][81].…”

Section: Minoxidilmentioning

confidence: 99%

Androgenetic Alopecia: a Review and Emerging Treatments

Alves¹

2017

CRDOA

View full text Add to dashboard Cite

Androgenetic Alopecia (AGA) is the most common noncicatricial alopecia that leads to the progressive miniaturization of the hair follicle. Scalp terminal hairs are converted into vellus hairs, primarily due to two factors: genetic predisposition and hormonal stimulation.The incidence and prevalence of AGA increases with age. The onset of AGA is gradual, and when this pathology progresses, the anagen phase shortens and the telogen phase remains constant. The shedding area varies from patient to patient and is usually most marked at the vertex in men, while women with AGA generally lose hair diffusely over the crown.Topical minoxidil and oral finasteride (5-alpha-reductase type II inhibitor) are the gold-standard therapies for AGA and are currently the only Food and Drug Administration (FDA)-approved drugs for the treatment of AGA.The currently available treatments for AGA are sometimes perceived as having limited effectiveness; therefore, the identification of new therapies for this pathology is of utmost importance.This article aims to review the pathogenesis, diagnosis of AGA and all the new emerging treatments for this entity in order to prevent its progression and improve the results of this pathology.

show abstract

“…Evaluations can be categorized as invasive (e g, scalp biopsies), semi-invasive (e g, trichogram), or noninvasive (e g, hair counts, microscopic evaluation, trichoscopy). Each of these approaches, when interpreted with the comprehensive clinical picture, can provide valuable insights into patient diagnosis, treatment and monitoring 7 .More recent studies have accumulated evidence that use of dermoscopy of hair and scalp (trichoscopy) in the clinical evaluation of hair disorders improves diagnostic capability beyond simple clinical inspection [8][9][10][11] . Without treatment, AGA takes a chronic progressive course with an average hair loss of 5-6 % annually with great inter individual variability 12,13 .…”

Section: % On the Basis Of Dermoscopic Analysis In Androgenetic Alomentioning

confidence: 99%

Comparative Study of Efficacy of Topical Minoxidil 5% and Combination of Topical Minoxidil 5%, Topical Azelaic Acid 1.5% and Topical Tretinoin 0.01% on the Basis of Dermoscopic Analysis in Androgenetic Alopecia

Gugle¹,

Jadhav²,

Kote³

et al. 2015

mvpjms

View full text Add to dashboard Cite

Background: Androgenetic alopecia (AGA) more commonly known as male pattern baldness affects up to 50% of men worldwide. Tretinoin prolongs anagen phase and increases percutaneous absorption of minoxidil three fold. Azelaic acid is an inhibitor of 5 alpha reductase and could be an effective agent in the treatment of androgen related pathology of human skin. Aims and Objective: 1) To study the efficacy of topical minoxidil 5% in treatment of androgenetic alopecia. 2) To study the efficacy of combination of topical minoxidil 5%, topical azelaic acid 1.5% and topical tretinoin 0.01% in treatment of androgenetic alopecia. 3) To compare the efficacy of foresaid topical preparation in treatment of androgenetic alopecia Setting: Outpatient department of Dermatology, Venerology Leprology of a tertiary health care centre with an attached medical college. Material and methods: Topical minoxidil 5 % lotion was used in 23 (50%) patients of the present study. Combination of topical minoxidil 5%, azelaic acid 1.5 % and tretinoin 0.01 % lotion was used in 23 (50 %) patients of the present study. Statistical analysis used: Epi info version 7. Results: There was statistically significant increase in hair number and thickness after treatment in both the groups. The comparison of the increase of hair number and thickness was statistically insignificant. Conclusions: Topical Minoxidil 5% is equally effective to combination of topical Minoxidil 5%, azelaic acid 1.5% and tretinoin 0.01% in treatment of androgenetic alopecia.

show abstract

Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment

Cited by 136 publications

References 1 publication

A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men

A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men

Androgenetic Alopecia: a Review and Emerging Treatments

Comparative Study of Efficacy of Topical Minoxidil 5% and Combination of Topical Minoxidil 5%, Topical Azelaic Acid 1.5% and Topical Tretinoin 0.01% on the Basis of Dermoscopic Analysis in Androgenetic Alopecia

Contact Info

Product

Resources

About